Refine your search

Clear

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa: Phase 3 Double-Blind Study. Participation will last approximately 71 weeks. Injection under the skin, Males/Females at least 18 years old with Hidradenitis Suppurativa (HS) Hidradenitis Suppurativa (HS), is an inflammatory skin condition that can come and go. It is characterized by painful spots, called lesions, that are found most commonly in the groin, armpits, and buttocks. These lesions are very painful and can drain and cause scarring. The purpose of this study is to find out if the study medicine, bimekizumab, can help with the treatment of HS.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04242446
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
HS lesions present in at least 2 locations (armpits, under breast, abdomen, groin, buttock),
Diagnosed with HS for at least 6 months
failed antibiotic treatment for HS
Exclusion Criteria:
certain medication are not allowed; study coordinator will provide more information
Diagnosis of sarcoidosis, Systemic lupus erythematosus, or active IBD
Have had a splenectomy
Positive test result for Hepatitis B or Hepatitis C
Have had major surgery in the past 3 months
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA